KAHR Medical

15 articles with KAHR Medical

• KAHR Announces First Patient Dosed in Phase 1/2 Clinical Trial of DSP107, Bi-Functional CD47x41BB Candidate for the Treatment of Solid Tumors

  11/12/2020

  KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, announced dosing of the first patient in its Phase 1/2 clinical trial assessing its lead product, DSP107, a bi-functional CD47x41BB candidate for the treatment of solid tumors.

• KAHR Announces Addition of Prof. Hagop M. Kantarjian to Its Clinical Advisory Board

  10/15/2020

  Prof. Hagop M. Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, has joined KAHR's clinical advisory board.

• KAHR Announces Oral Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting

  10/12/2020

  Data for DSP107, first-in-class bi-functional CD47x41BB targeting compound, to be presented on December 5, 2020

• KAHR Announces Two Key Appointments to Strengthen Leadership Team

  10/5/2020

  KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, announced that Aron Knickerbocker has been appointed Director and that Bryan Jennings has been appointed Chief Financial Officer of KAHR.

• KAHR Medical Announces FDA Clearance of IND Application for DSP107, anti-CD47 Candidate for the Treatment of Solid Tumors

  8/12/2020

  Phase I/II study in patients with solid tumors expected to commence in Q3 2020 at leading sites in the United States

• KAHR Medical Raises $18 Million in Private Funding Round

  2/25/2020

  Funds will be used for advancing the Company's next generation immuno-oncology drug candidates, including lead anti-CD47 product for the treatment of solid tumors through Phase I/II study in addition to advancing preclinical pipeline

• KAHR Medical Announces Clinical Trial Collaboration to Evaluate DSP107 in Combination With a PD-L1 Checkpoint Inhibitor in Advanced Lung Cancer Patients

  9/9/2019

  KAHR Medical announced a new clinical collaboration with Roche.

• KAHR Medical Reports Raising $12 Million At First Closing Of Its Series B Private Equity Financing

  12/15/2015

• KAHR Medical, a Hadasit Bio Holdings Portfolio Company, to Raise $2.5M

  9/11/2013

• KAHR Medical Granted U.S. Patent Approval for One of Its Lead Products in Development, KAHR-101

  2/4/2013

• Hadasit Bio-Holdings Ltd. Portfolio Companies - ProtAb Ltd. and KAHR Medical to Receive NIS 10.7 Million (Over $2.8 Million USD) in Additional Government Grants

  1/28/2013

• KAHR Medical, a Hadasit Bio-Holdings Ltd. Portfolio Company, to Raise $2.6 Million

  6/19/2012

• Recipharm AB and KAHR Medical Announce Continuation of Partnership in the Development of KAHR-102

  6/20/2011

• KAHR Medical And Cobra BioManufacturing Partner to Develop Trans Signal Converter Protein Production

  5/11/2009

• KAHR Medical Raises $500K From Hadasit Bio Holdings and the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor of Israel

  1/28/2009